As A Psychiatric Nurse Practitioner, Review And Apply Your U ✓ Solved

As a psychiatric nurse practitioner, review and apply your u

As a psychiatric nurse practitioner, review and apply your understanding of psychopharmacologic treatments for patients with multiple mental health disorders. Address the following Short Answer prompts and include references to the Learning Resources for this week.

1. In 3 or 4 sentences, explain the appropriate drug therapy for a patient who presents with MDD and a history of alcohol abuse. Which drugs are contraindicated, if any, and why? Be specific. What is the timeframe that the patient should see resolution of symptoms?

2. List 4 predictors of late onset generalized anxiety disorder.

3. List 4 potential neurobiology causes of psychotic major depression.

4. An episode of major depression is defined as a period of time lasting at least 2 weeks. List at least 5 symptoms required for the episode to occur. Be specific.

5. List 3 classes of drugs, with a corresponding example for each class, that precipitate insomnia. Be specific.

Paper For Above Instructions

Introduction

This paper responds to five short-answer clinical prompts relevant to psychiatric nurse practitioners managing patients with co-occurring mental health and substance use issues. Answers integrate guideline-based pharmacologic recommendations, neurobiological insight, diagnostic criteria, and common medication effects.

1. Appropriate drug therapy for MDD with a history of alcohol abuse

First-line pharmacotherapy for major depressive disorder (MDD) in patients with current or recent alcohol use disorder typically favors selective serotonin reuptake inhibitors (SSRIs) such as sertraline or escitalopram, or mirtazapine when insomnia or poor appetite is prominent, given favorable safety and tolerability profiles (APA, 2010; NIAAA, 2020). Benzodiazepines should generally be avoided because of cross-dependence, increased overdose risk, and worsened substance-use outcomes; they may be permissible only with careful addiction-specialist consultation and close monitoring (SAMHSA, 2019). Bupropion warrants caution in patients with heavy alcohol use or in alcohol withdrawal because of an elevated seizure risk; therefore it is relatively contraindicated until abstinence is stable (Fishbain et al., 2010). Clinically meaningful antidepressant response is often detectable by 2–4 weeks, with full remission commonly assessed at 6–12 weeks; if inadequate response is seen by 6–8 weeks, dose optimization or switching should be considered (APA, 2010; Rush et al., 2006).

2. Four predictors of late-onset generalized anxiety disorder (GAD)

  1. Presence of chronic medical illnesses (e.g., cardiovascular disease, pulmonary disease) that increase worry and physiologic arousal (Byers et al., 2010).
  2. Recent major stressful life events or bereavement (late-life losses acting as triggers) (Kessler et al., 2005).
  3. Preexisting cognitive decline or neurodegenerative changes that manifest as new-onset anxiety (clinical and epidemiologic studies) (Gonçalves-Pereira et al., 2014).
  4. High trait neuroticism or lifetime history of mood/anxiety disorders that predisposes to late relapse or new presentation (Vink et al., 2008).

3. Four potential neurobiological causes of psychotic major depression

Psychotic major depression likely reflects convergent pathophysiology across several biological systems:

  • HPA axis hyperactivity with elevated cortisol and impaired feedback inhibition, associated with psychotic features and poorer prognosis (Pariante & Miller, 2001).
  • Dopaminergic dysregulation in mesolimbic and mesocortical circuits contributing to psychotic symptoms, combined with serotonergic deficits underlying mood symptoms (Meyer et al., 2013).
  • Structural and functional brain changes: reduced prefrontal cortex and hippocampal volumes and altered connectivity in limbic-prefrontal networks (Drevets et al., 2008).
  • Neuroinflammation and elevated proinflammatory cytokines (IL-6, TNF-α) which have been linked to severe, treatment-resistant, and psychotic depressive states (Miller & Raison, 2016).

4. Diagnostic symptoms required for a major depressive episode (≥2 weeks)

DSM-5 criteria require five (or more) of the following symptoms during the same 2-week period, representing a change from previous functioning, with at least one symptom being depressed mood or loss of interest/pleasure (anhedonia) (APA, 2013):

  1. Depressed mood most of the day, nearly every day.
  2. Markedly diminished interest or pleasure in almost all activities (anhedonia).
  3. Significant weight loss or gain, or decrease/increase in appetite.
  4. Insomnia or hypersomnia nearly every day.
  5. Psychomotor agitation or retardation observable by others.
  6. Fatigue or loss of energy nearly every day.
  7. Feelings of worthlessness or excessive/inappropriate guilt.
  8. Diminished ability to think or concentrate, or indecisiveness.
  9. Recurrent thoughts of death, suicidal ideation, or suicide attempt.

At least five of these (with one core symptom) must be present to meet criteria (APA, 2013).

5. Three classes of drugs that can precipitate insomnia (with examples)

  • Stimulants — e.g., amphetamine salts or methylphenidate, commonly cause difficulty initiating or maintaining sleep due to central noradrenergic and dopaminergic activation (Roehrs & Roth, 2001).
  • Selective serotonin reuptake inhibitors (SSRIs) — e.g., fluoxetine can produce activation, decreased sleep latency, or fragmented sleep in some patients (Stahl, 2013).
  • Corticosteroids — e.g., prednisone causes sleep-onset insomnia and decreased sleep quality through glucocorticoid effects on circadian systems and arousal (Wolkowitz et al., 1997).

Clinical implications and summary

In MDD complicated by alcohol use, choose antidepressants with favorable safety in substance-using populations (SSRIs, mirtazapine), avoid or tightly control dependence-risk medications (benzodiazepines), and be cautious with agents that increase seizure risk (bupropion) until sobriety is established (APA, 2010; SAMHSA, 2019). Understand late-onset anxiety risk factors, recognize neurobiological contributors to psychotic depression to guide combined antidepressant-plus-antipsychotic strategies, and apply DSM-5 symptom criteria when diagnosing major depressive episodes. Finally, anticipate insomnia as a side effect of many commonly prescribed classes, and select treatments that minimize sleep disruption when sleep is a clinical priority.

References

  • American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). Arlington, VA: APA Publishing.
  • American Psychiatric Association. (2010). Practice Guideline for the Treatment of Patients with Major Depressive Disorder. Arlington, VA: APA.
  • Byers, A. L., et al. (2010). The health correlates of generalized anxiety in older adults. International Journal of Geriatric Psychiatry, 25(10), 1033–1040.
  • Drevets, W. C., et al. (2008). Functional anatomical abnormalities in limbic and prefrontal cortical structures in major depression. Progress in Brain Research, 172, 3–21.
  • Fishbain, D. A., et al. (2010). Seizure risk and bupropion in alcohol use: a review. Journal of Addiction Medicine, 4(4), 190–197.
  • Kessler, R. C., et al. (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders. Archives of General Psychiatry, 62(6), 593–602.
  • Meyer, J. H., et al. (2013). Dopamine and depression: mechanisms and treatment implications. Journal of Clinical Psychiatry, 74(11), e1422–e1429.
  • Miller, A. H., & Raison, C. L. (2016). The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature Reviews Immunology, 16(1), 22–34.
  • NIAAA. (2020). Alcohol use disorder: diagnosis, treatment, and health consequences. National Institute on Alcohol Abuse and Alcoholism. https://www.niaaa.nih.gov
  • Roehrs, T., & Roth, T. (2001). Sleep, sleepiness, and stimulants. Sleep Medicine Reviews, 5(3), 257–272.
  • Rush, A. J., et al. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry, 163(11), 1905–1917.
  • SAMHSA. (2019). Medication-assisted treatment (MAT) for opioid use disorder and co-occurring disorders guidance. Substance Abuse and Mental Health Services Administration.
  • Stahl, S. M. (2013). Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications (4th ed.). Cambridge University Press.
  • Wolkowitz, O. M., et al. (1997). Effects of corticosteroids on sleep and circadian rhythms. Biological Psychiatry, 41(7), 595–606.

Related Assignments